OKYO Pharma Ltd (NASDAQ:OKYO), which is developing its therapeutic urcosimod to treat neuropathic corneal pain, announced that its CEO Dr Gary Jacob will present at the Ophthalmology Innovation Summit (OIS) XV in San Diego on November 22.
"We are thrilled to showcase our progress with urcosimod at OIS XV, a cornerstone event for ophthalmic innovation," Jacob said. “The OIS XV meeting will allow us to engage with key opinion leaders and potential partners to accelerate our development of urcosimod for patients who desperately need effective therapies."